Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CI-1033 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CI-1033 | DRUG | - |
Inclusion Criteria: * Female, at least 18 years of age * Histologically confirmed diagnosis of breast cancer * Metastatic (Stage IV) disease * Progressive or recurrent disease following the most recent therapy * No more than 2 different, prior cytotoxic chemotherapy regimens for metastatic disease ...
CI 1033 is an investigational small molecule being studied for the treatment of lung neoplasms, breast neoplasms, and non-small cell lung carcinoma. It has been evaluated in clinical trials for advanced non-small cell lung cancer, metastatic breast cancer, and as a first-line chemotherapy combination in non-small cell lung cancer patients.
CI 1033 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. The drug is an investigational small molecule in the oncology therapeutic area, and it has been studied in clinical trials for various cancer indications.
CI 1033 is in Phase 1 clinical development. It has completed three clinical trials, including two Phase 2 studies and one Phase 1 study. The drug is investigational and has not been approved by regulatory authorities.
CI 1033 has been studied in three completed clinical trials: NCT00050830, a Phase 2 study in advanced non-small cell lung cancer; NCT00051051, a Phase 2 study in metastatic breast cancer; and NCT00174356, a Phase 1 study combining CI 1033 with paclitaxel and carboplatin in non-small cell lung cancer.
Yes, CI 1033 and CI-1033 refer to the same drug. The name appears in clinical trial records with and without a hyphen, but both refer to the investigational small molecule being developed by Pfizer for the treatment of lung and breast cancers.